Fierce Pharma
Fierce Biotech
Fierce Healthcare
Fierce Life Sciences Events
Advertise
About Us
Biotech
Cell & Gene Therapy
Clinical Data
Venture Capital
Deals
Research
Medtech
Devices
Diagnostics
AI and Machine Learning
CRO
Special Reports
Trending Topics
Biologics
Clinical Development
Fierce 50
Special Report
Awards Gala
Resources
Fierce Events
Industry Events
Webinars
Podcasts
Whitepapers
Survey
Events
Subscribe
Trending T
Biotech
Cell & Gene Therapy
Clinical Data
Venture Capital
Deals
Research
Medtech
Devices
Diagnostics
AI and Machine Learning
CRO
Special Reports
Trending Topics
Biologics
Clinical Development
Fierce 50
Special Report
Awards Gala
Resources
Fierce Events
Industry Events
Webinars
Podcasts
Whitepapers
Survey
Events
Subscribe
Fierce Pharma
Fierce Biotech
Fierce Healthcare
Fierce Life Sciences Events
Advertise
About Us
dry eye disease
Biotech
Bausch + Lomb pens $485M-plus biobucks pact with City Tx
City Therapeutics has inked a new deal with Bausch + Lomb for a gene silencing approach to the eye disorder geographic atrophy.
Ben Adams
Jan 10, 2025 6:37am
Aldeyra preps for FDA refiling as dry eye drug hits ph. 3 goal
Aug 8, 2024 10:48am
Oculis sees promise in dry eye disease subgroup, plans phase 3
Jun 10, 2024 7:20am
Palatin plans phase 3 tweaks after dry eye study misses primary
Feb 28, 2024 10:25am
Alcon’s $770M Aerie takeover delivers phase 3 dry eye wins
Jan 10, 2024 5:40am
With FDA rejection for eye drug, Aldeyra plans speedy new trial
Nov 28, 2023 4:30am
